Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
That’s according to an analysis of four large health systems from around the United States.
A new report by the National Viral Hepatitis Roundtable tracks the progress.
A national survey gauges HIV care providers’ views about the Affordable Care Act.
The drugs are set to come out in January 2019 with a list price of $24,000 for the most common dose for each.
New recommendations in the Annals of Internal Medicine would increase access to treatment.
The idea is being referred to as a “subscription-based” model.
It is one of 12 states that still limits medications to only the sickest patients.
The case alleged that the state’s Medicaid system was setting too many barriers for HCV-positive patients.
Medi-Cal will soon begin providing treatment access to almost all state-insured patients living with the virus.
That is compared with people who have hep C who had other types of insurance coverage.
The denial rate, which is higher for the privately insured than those with Medicaid or Medicare, is on the rise.
Oregon has held on to restrictive Medicaid requirements, despite expert recommendations not to.
This is according to an analysis of hep C treatment rates at four large urban hospital systems.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.